Autonomix Medical, Inc. Announces Abstract Selected for Poster Presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

Rhea-AI Summary

Autonomix Medical (NASDAQ: AMIX) announced its abstract was accepted for a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, CA, January 8-10, 2026.

The poster, titled "Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation," is Abstract 693 and will be presented by Robert S. Schwartz, MD, Chief Medical Officer. Session: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract. Presentation times: January 9, 2026, 11:30 AM–1:00 PM and 5:00 PM–6:00 PM PST.

Key Figures

Abstract number 693 ASCO GI 2026 poster selection

Symposium dates January 8–10, 2026 ASCO Gastrointestinal Cancers Symposium schedule

Poster date January 9, 2026 Poster Session B: pancreas/small bowel/hepatobiliary cancers

Session times 11:30 AM–1:00 PM and 5:00 PM–6:00 PM PST ASCO GI 2026 poster presentation windows

Market Reality Check

$0.5371 Last Close

Volume Volume 536,223 is in line with 20-day average 537,725. normal

Technical Shares at $0.6031 are trading below the 200-day MA of $1.39 and near the 52-week low of $0.6013.

Peers on Argus

While AMIX was down 4.57%, several peers like MOVE (-9.73%) and HSDT (-8.6%) also declined, but scanner data did not flag a coordinated sector momentum move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 26	Strategy update	Positive	+10.2%	CEO Corner segment outlining IP protection and expansion beyond pancreatic cancer.
Nov 18	Private placement	Negative	-17.4%	At‑the‑market priced $5.0M private placement with shares and Series C warrants.
Nov 17	Clinical data update	Positive	+58.2%	Post‑hoc PoC subgroup analysis showing sustained quality‑of‑life improvements.
Oct 24	Conference presentations	Positive	+0.0%	TCT conference podium talks on first‑in‑human PoC pancreatic cancer pain study.
Oct 16	Investor conference	Positive	-1.8%	Maxim Growth Summit appearance focused on nerve‑sensing and ablation platform.

Pattern Detected

Recent news has often produced price reactions aligned with the apparent sentiment: positive clinical or strategy updates saw gains, while financing actions weighed on shares, with conference/investor events sometimes seeing muted or negative moves.

Recent Company History

Over the past few months, AMIX has highlighted its nerve-targeted platform across multiple channels, from the Oct 25–28, 2025 TCT conference podium presentations to a Nov 26, 2025 CEO Corner on strategic growth. Positive pancreatic cancer proof-of-concept data on Nov 17, 2025 corresponded with a strong gain, while the $5.0 million private placement on Nov 18, 2025 coincided with a sharp decline. Today’s ASCO GI poster selection extends this pattern of clinical and visibility milestones following earlier PoC results.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-11-26

$7.7 million registered capacity

An effective S-3 shelf dated Nov 26, 2025 registers 13,504,998 warrant-related shares for resale. While the company receives no proceeds from resales, it could obtain up to $7.7 million in gross proceeds if all common warrants at $0.8607 are exercised in cash, implying potential dilution alongside added funding capacity.

Market Pulse Summary

This announcement highlights selection of Autonomix’s pancreatic cancer pain data for poster presentation at the ASCO GI 2026 symposium, extending visibility following earlier proof‑of‑concept results. Historically, clinical data updates, such as the Nov 17, 2025 subgroup analysis, have coincided with strong moves, while financings like the $5.0 million private placement weighed on shares. Investors may watch future clinical milestones, liquidity measures, and use of the S-3 covering 13,504,998 warrant-related shares and up to $7.7 million in potential proceeds.

Key Terms

pancreatic adenocarcinoma medical

"Title: Pain mitigation in pancreatic adenocarcinoma: A long-term analysis..."

Pancreatic adenocarcinoma is a type of cancer that starts in the cells of the pancreas, the organ that helps digestion and controls blood sugar. It matters to investors because it is often aggressive and hard to detect early, so progress or setbacks in diagnostics, drugs or clinical trials can strongly affect the value of companies working on treatments—similar to how a breakthrough or failure in fixing a critical bridge can change the fortunes of contractors and insurers.

denervation medical

"A long-term analysis of denervation via transvascular RF energy-based ablation"

Denervation is the loss or deliberate interruption of nerve signals to a specific organ or tissue, often achieved by cutting, destroying, or blocking nerves. Like unplugging a lamp to stop it from turning on, denervation is used as a medical approach to reduce unwanted activity such as high blood pressure or chronic pain; for investors it matters because devices and drugs that perform or affect denervation can drive clinical outcomes, regulatory decisions, safety profiles, and market opportunities.

transvascular medical

"A long-term analysis of denervation via transvascular RF energy-based ablation"

Transvascular describes medical procedures, devices or approaches that are performed through the body's blood vessels rather than by open surgery. Think of it like threading a tiny tool through plumbing to reach a problem inside, which often means smaller incisions, faster recovery and different regulatory and reimbursement pathways. Investors watch transvascular products because they can change clinical practice, drive demand for specialized devices and affect approval, adoption and reimbursement risk for healthcare companies.

RF energy-based ablation medical

"A long-term analysis of denervation via transvascular RF energy-based ablation"

A medical procedure that uses controlled radiofrequency (RF) electrical energy to heat and destroy targeted tissue, such as tumors, abnormal heart pathways, or nerves causing pain. Investors care because RF ablation devices, disposable probes, and related services drive sales, regulatory review, and reimbursement decisions; adoption rates and clinical outcomes influence demand much like how a more effective tool can replace older equipment in a workshop.

AI-generated analysis. Not financial advice.

THE WOODLANDS, TX, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced its abstract has been accepted for poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, being held January 8-10, 2026 in San Francisco, CA.

Details of the poster presentation are as follows:

Title: Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation
Abstract Number: 693
Presenter: Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical, Inc.
Session Title: Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Date and Time: January 9, 2026 from 11:30 AM-1:00 PM and 5:00 PM-6:00 PM PST

About ASCO

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to the principle that knowledge conquers cancer. Together with the Association for Clinical Oncology, ASCO represents more than 50,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of high quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports ASCO by funding groundbreaking research and education across cancer’s full continuum.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Investor and Media Contact

JTC Team, LLC
Jenene Thomas
833-475-8247
autonomix@jtcir.com

FAQ

When will Autonomix Medical (AMIX) present at the 2026 ASCO Gastrointestinal Cancers Symposium?

Autonomix will present on January 9, 2026 during Poster Session B with times listed as 11:30 AM–1:00 PM and 5:00 PM–6:00 PM PST.

What is the title of the AMIX poster at ASCO GI 2026 and what is its abstract number?

The poster is titled "Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation" and is Abstract 693.

Who is presenting Autonomix Medical's (AMIX) poster at the ASCO GI 2026 symposium?

The poster will be presented by Robert S. Schwartz, MD, Chief Medical Officer of Autonomix Medical.

Where and when is the 2026 ASCO Gastrointestinal Cancers Symposium taking place for AMIX's presentation?

The symposium runs January 8–10, 2026 in San Francisco, CA; Autonomix's poster is scheduled for January 9, 2026.

How can investors find the Autonomix (AMIX) poster session details at ASCO GI 2026?

Investors can locate the poster by searching for Abstract 693 in the ASCO Gastrointestinal Cancers Symposium program under Poster Session B.